Please login to the form below
PD-1
This page shows the latest PD-1 news and features for those working in and with pharma, biotech and healthcare.
FDA approval for Merck’s Keytruda threatens Libtayo in skin cancer
Approval of Merck’s market-leading PD-1 inhibitor in this indication is a shot across the bows of Sanofi and Regeneron, which picked up FDA approval for Libtayo in cSCC – ... Libtayo was the sixth drug in the PD-1/PD-L1 inhibitor class to reach the
Latest news
-
Gilead spends $275m on half-share in immuno-oncology firm Pionyr
Gilead’s interest in Pionyr lies in the biotech’s ‘Myeloid Tuning’ therapies – headed by preclinical-stage antibodies PY314 and PY159 – which have shown promising results in combination with ... PD-L1-targeting checkpoint inhibitors.
-
AZ’s Imfinzi gets US OK in small cell lung cancer, challenging Tecentriq
The green light makes Imfinzi (durvalumab) the first PD-1/PD-L1 inhibitor to challenge Roche’s Tecentriq (atezolizumab) in ES-SCLC, which became the first checkpoint inhibitor to be approved
-
In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa
Another is Libtayo (cemiplimab), its latecomer checkpoint inhibitor which has however the first drug in the PD-1/PD-L1 class to be approved for cutaneous squamous cell carcinoma (CSCC), a
-
Immutep slumps on latest efti data in breast cancer
Immutep saw its share leap and then crash last month, after it reported phase 2b data for efti alongside Merck &Co’s PD-1 inhibitor Keytruda (pembrolizumab) in non-small cell
-
Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer
1/PD-L1 inhibitors spilling across a number of cancer types and ramping up the competition. ... However, Bavencio lagged behind Keytruda even in that indication, after Merck &Co’s PD-1 inhibitor beat it to the punch after winning approval in RCC a few
More from news
Approximately 28 fully matching, plus 345 partially matching documents found.
Latest Intelligence
-
Encouraging signs in biomarker R&D
The confounding issue is that, in the case of PD-1/PD-L1 drugs, each developer uses its own companion diagnostic that is required to prescribe the drug. ... Harmonisation has been addressed in this case by the development of a ‘complementary’
-
2019: CRISPR and therapeutic gene editing comes of age
The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the ... hope was that - without the brake of PD-1 – the edited cells
-
Immuno-oncology in 2019: the rapid evolution continues
However this class of drugs aren’t miracle cures: many patients and tumour types do not respond to PD-1/PD-L1s – the overall response rate (ORR) is commonly well below ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.
-
Drug launches to watch in 2019
9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... 1 inhibitor Keytruda (pembrolizumab) was backed for cancers
-
Is China ready for a pharmaceutical gold rush?
The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours. ... Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.
More from intelligence
Approximately 0 fully matching, plus 34 partially matching documents found.
Latest appointments
-
Crescendo Biologics appoints Dr Kevin Johnson as chairman
Crescendo's discovery programmes are focused on the development of innovative medicines for the treatment of cancer, including its proprietary Humabody Drug Conjugates (HDCs) and checkpoint modulators such as ... 1 Humabodies.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Oncosec
with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders.
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
patients whose disease was truly refractory to anti–PD-1 antibody monotherapy.17. ... Initial report of intratumoral tavokinogene telseplasmid with pembrolizumab in advanced melanoma: an approach designed to convert PD-1 antibody progressors into
-
Immuno-oncology: The market opportunity for PD-1/PD-L1s
Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1 market at this time.
-
How pembrolizumab will change the management of advanced lung cancer
The Phase III KEYNOTE-024 trial assessed pembrolizumab compared to standard of care (SOC) platinum-based chemotherapies in patients with previously untreated stage IV, programmed cell death ligand 1 (PD-L1) ... In light of these findings, it is
-
A stumble, but not a fall – what’s next for Opdivo?
Until things took a turn for the worse. . Opdivo works via PD-1 immune checkpoint inhibition, which involves reactivating T-cells (a subtype of white blood cell) and decreasing tumor growth.
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- Sinovac reveals positive preliminary data for COVID-19 vaccine
- Finalists 2020 - Communiqué Awards
- Novartis pulls EU filing for $3.4bn eye therapy Xiidra
- Novo Nordisk gets another OK for oral GLP-1 drug Rybelsus
- Remdesivir closes in on receiving first EU approval for treatment for COVID-19
- Syneos Health appoints trio of senior hires
- Syneos Health appoints Tim Pantello as president of communications
- The best work in healthcare communications shines at virtual Communiqué Awards
- Mearns & Pike, Electric Putty and Evoke KYNE make a clean sweep at Communiqué 2020
- 90TEN scoops Communiqué Communications Consultancy of the Year Award for the Second Year Running
- NHS test and trace system ‘still not good enough’ says health leader
PMHub
Pegasus
Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...
Latest intelligence
- The search for treatments for Parkinson’s disease
- The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
- Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
- Ditch the Label – it’s just me....
- The impact of COVID-19 on clinical trials
- As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...
Quick links
Infographics
